Ogluo

RSS

glucagon

Authorised
This medicine is authorised for use in the European Union.

Overview

Ogluo is a medicine for treating severe hypoglycaemia (very low levels of glucose in the blood) in patients with diabetes who are at least 2 years old.

Hypoglycaemia can occur when diabetes medicines to reduce blood glucose cause glucose levels to fall too low. In severe cases, patients can faint or become unconscious and they must be treated urgently to raise glucose levels.

Ogluo contains the active substance glucagon.

Ogluo is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance. However, Ogluo is available as a solution for injection while the reference medicine is available as a powder that needs to be dissolved to make up the injection. The reference medicine for Ogluo is GlucaGen.

This EPAR was last updated on 26/05/2023

Authorisation details

Product details
Name
Ogluo
Agency product number
EMEA/H/C/005391
Active substance
Glucagon
International non-proprietary name (INN) or common name
glucagon
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
H04AA01
Publication details
Marketing-authorisation holder
Tetris Pharma B.V
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
11/02/2021
Contact address

Element Offices
Bargelaan 200
2333 CW Leiden
NETHERLANDS

Product information

01/02/2023 Ogluo - EMEA/H/C/005391 - IB/0009

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Pancreatic hormones

  • Glycogenolytic hormones

Therapeutic indication

Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Assessment history

How useful was this page?

Add your rating
Average
1 rating